Navigation Links
MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Date:3/24/2008

ompared to the currently marketed conventional nebulized budesonide," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "These results are consistent with our previous clinical studies, and we believe provide additional support for the safety of our next generation pediatric asthma therapy."

The company plans to present the results from this study at a future scientific conference.

About Unit Dose Budesonide

MAP Pharmaceuticals is developing Unit Dose Budesonide, a novel version of nebulized budesonide for treating pediatric asthma in children from 12 months to eight years of age. Budesonide is an inhaled corticosteroid that has been used for more than 20 years with demonstrated safety and efficacy. It is the only corticosteroid approved for treating asthma in pregnant women and in children as young as 12 months old. UDB is designed to be administered more quickly and to provide efficacy at a lower corticosteroid label dose than the commercially available product.

About Pediatric Asthma

Of the estimated 20 million diagnosed asthma patients in the United States, approximately 6.8 million are children under 18 years of age and approximately 1.2 million are children under five years of age. Guidelines released in 2007 recommend the prophylactic use of inhaled corticosteroids (ICS) as the preferred initial treatment to reduce inflammation and maintain long-term control of asthma in children of all ages.

In the United States, children under the age of five typically use a nebulizer to receive inhaled corticosteroid medication because they lack the breath coordination needed to use pressurized metered-dose inhalers or they lack the lung capacity needed to use dry powder inhalers. The current goal of asthma management is, with proper treatment, to allow children with asthma to lead active lives.

Since the introduction of conventional nebulized budesonide, annual sales have grown to approxi
'/>"/>

SOURCE MAP Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Vasomedical, Inc. ("Vasomedical") (OTC Bulletin Board: ... announced financial results of the three months ended November ... noninvasive treatment of cardiovascular diseases. In addition, the Company, ... , commenced operations on July 1, 2010 under its ...
... (NYSE: CVS ) today announced that it ... jointly lead its CVS/pharmacy business, reporting directly to Larry ... Effective immediately, Mike Bloom, EVP Merchandising and Supply Chain, ... will take over the management of the company,s retail ...
Cached Medicine Technology:Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 2Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 3Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 4CVS Caremark Announces Interim Leadership for Retail Business 2CVS Caremark Announces Interim Leadership for Retail Business 3
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... affects about one in five infants in the United ... the first several months after birth. Research into probiotic ... however, the April 1, 2014 issue of the ... a study, "Probiotics and Infant Colic," concluding that the ... infant colic did not reduce crying or fussing ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... international team led by researchers at UC Davis has ... a key role in cell division, also boosts the ... first time the complex has been shown to perform ... an excellent target to control cellular energy production, potentially ... published online today in the journal Developmental Cell ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... When a child is farsighted or has astigmatism or ... develop. In contrast to single-eye amblyopia or lazy eye, ... brain, bilateral amblyopia affects both eyes and is less ... of the American Journal of Ophthalmology, researchers report that ...
... popular prostate cancer treatment called androgen deprivation therapy may ... makes them more likely to spread throughout the body, ... , Although the finding could eventually lead to changes ... the Johns Hopkins researchers caution that their discovery is ...
... after injury, study finds , MONDAY, Oct. 1 (HealthDay News) ... make it more resistant to damage than hearts unaffected by ... , Researchers at the University of Bristol and the Bristol ... prone to fatty build-up in the coronary arteries. One group ...
... the ,off, switch may reverse the chance of trouble down the ... your toddler is watching a lot of TV, turn it off ... the conclusion of a new study that suggests that the negative ... overcome by limiting viewing before the age of 6. , The ...
... WESTCHESTER, Ill. One of the first large-scale studies to ... function in a community dwelling of older women finds that ... women during the daytime, according to a study published in ... study, authored by Suzanne E. Goldman, PhD, of the University ...
... (PMS) perceive their sleep quality to be poorer in ... phase, despite there being no specific alterations in sleep ... published in the October 1 issue of the journal ... PhD, of the Human Sleep Research Program at SRI ...
Cached Medicine News:Health News:Early treatment of children with bilateral amblyopia essential, according to multisite study 2Health News:Standard treatment for prostate cancer may encourage spread of disease 2Health News:Coronary Disease Might Toughen Up Heart 2Health News:Kids' TV Viewing Tied to Behavioral Problems 2Health News:Kids' TV Viewing Tied to Behavioral Problems 3Health News:Journal SLEEP: disturbed sleep linked to poorer daytime function in older women 2Health News:Journal SLEEP: disturbed sleep linked to poorer daytime function in older women 3Health News:Women with severe PMS perceive their sleep quality to be poor 2
An intermediate set providing a greater range of telescopes than the starter set....
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut...
... up to 20 tilting ... in the vertical, horizontal ... the option to offset ... transillumination., ,Filters include Cobalt ...
With a high lens and filter range this ophthalmoscope is ideal for the Primary Care Specialist...
Medicine Products: